FDA delays action date for GSK's diabetes drug albiglutide

08/4/2013 | Reuters

The FDA has postponed its decision for three months on GlaxoSmithKline's type 2 diabetes drug albiglutide, saying now that a decision will come on April 15. The approval process in Europe for the once-weekly, injectable GLP-1 drug is moving ahead on schedule.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX